United Therapeutics Drops Ovarian Cancer Compound Following Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
With cancer pipeline empty, firm tells DAILY it will focus mainly on planned 2008 NDA for hypertension treatment Viveta.